HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +5.1% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 502.79K | $49.11M | n/a | n/a |
| Q2 2026 | 131 | -1 | 91.15M | $6.60B | +6 | −8 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | n/a | n/a |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | n/a | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | n/a | −1 |
| Q2 2024 | 14 | n/a | 8.14M | $426.06M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 13.20M | n/a | $686.67M | 0.0% | n/c | 1 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (passive) | 12.25M | n/a | $637.02M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 5.94M | -1.9% | $308.74M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | Arrowstreet Capital ✦ | 2.54M | +127.8% | $132.19M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.43M | -23.2% | $126.56M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | T. Rowe Price ✦ | 1.03M | -13.0% | $53.70M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 1.02M | +64.4% | $53.00M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Norges Bank ✦ (passive) | 865.57K | +3.8% | $45.03M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Capital World Investors ✦ | 782.00K | +4.5% | $40.68M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Millennium Management ✦ | 690.47K | +1534.9% | $35.92M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 439.84K | -31.9% | $22.88M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | Marshall Wace ✦ | 389.13K | -16.1% | $20.24M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 381.75K | -8.6% | $19.86M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 378.80K | +1043.1% | $19.71M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 15 | Renaissance Technologies ✦ | 338.61K | +182.2% | $17.61M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 311.40K | +292.1% | $16.20M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 17 | Wellington Management ✦ | 103.67K | +94.5% | $5.39M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 18 | Fidelity (FMR) ✦ | 84.56K | n/a | $4.40M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 19 | Gotham Asset Management ✦ | 68.05K | +109.2% | $3.54M | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 630 holders, 119.44M shares, $7.40B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 200 sh · $22,102
Officer, Director · 11.90K sh · $1.31M
Officer, Director · 3.09K sh · $336,526
Officer, Director · 4.81K sh · $520,341
Officer, Director · 8.60K sh · $954,867
Officer, Director · 200 sh · $22,739
Officer, Director · 900 sh · $101,502
Officer, Director · 10.30K sh · $1.15M
Officer, Director · 1.78K sh · $197,245
Officer, Director · 9.92K sh · $1.09M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology